Transcriptomic Biomarker Analysis – Leukemia, Lymphoma, Myeloma

Hematologic cancers, such as leukemia, lymphoma, and myeloma, require in-depth gene expression analysis to refine diagnosis, assess prognosis, and guide therapeutic decisions. Identifying molecular biomarkers is essential for personalized treatments and disease monitoring.

Genes Analyzed in Hematologic Cancers

Our panel targets key biomarkers involved in the malignant transformation of blood cells, including:

• BCR-ABL1 – Genetic fusion characteristic of chronic myeloid leukemia (CML)

• IGH@, IGK@, IGL@ – Immunoglobulin rearrangements in B-cell lymphomas

• MYC – Overexpression associated with aggressive lymphomas (Burkitt, DLBCL)

• TP53 – Mutation affecting prognosis in leukemia and lymphoma

• FLT3, NPM1, CEBPA – Prognostic markers in acute myeloid leukemia (AML)

• JAK2 V617F – Mutation involved in myeloproliferative disorders

• CD38, BCMA – Therapeutic targets in multiple myeloma

Applications & Benefits

• Patient stratification based on molecular alterations

• Subtype identification in leukemia and lymphoma for targeted treatment

• Minimal residual disease (MRD) monitoring through transcriptomics

• Tracking treatment efficacy for targeted therapies and immunotherapies

Technologies Used

We employ cutting-edge technologies to ensure sensitive and reliable analysis:

• RT-qPCR and RNA-seq (NGS) for detecting fusion transcripts and mutations

• Nanostring and transcriptomic arrays for multiplex biomarker analysis

• Flow cytometry combined with transcriptomics for enhanced characterization of cell populations

Contact us at contact@genxmap.com for an analysis tailored to your hematology and molecular oncology projects!